- Home
- PHH vs AVBP Comparison
PHH vs AVBP Comparison
Compare PHH & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHH
- AVBP
- Stock Information
- Founded
- PHH 2016
- AVBP 2021
- Country
- PHH China
- AVBP United States
- Employees
- PHH N/A
- AVBP N/A
- Industry
- PHH Package Goods/Cosmetics
- AVBP
- Sector
- PHH Consumer Discretionary
- AVBP
- Exchange
- PHH Nasdaq
- AVBP NYSE
- Market Cap
- PHH 894.1M
- AVBP 862.8M
- IPO Year
- PHH 2024
- AVBP 2024
- Fundamental
- Price
- PHH $0.81
- AVBP $21.02
- Analyst Decision
- PHH
- AVBP Strong Buy
- Analyst Count
- PHH 0
- AVBP 8
- Target Price
- PHH N/A
- AVBP $38.38
- AVG Volume (30 Days)
- PHH 3.2M
- AVBP 332.2K
- Earning Date
- PHH 01-01-0001
- AVBP 08-13-2025
- Dividend Yield
- PHH N/A
- AVBP N/A
- EPS Growth
- PHH N/A
- AVBP N/A
- EPS
- PHH 0.02
- AVBP N/A
- Revenue
- PHH $2,381,851.00
- AVBP N/A
- Revenue This Year
- PHH N/A
- AVBP $85.82
- Revenue Next Year
- PHH N/A
- AVBP N/A
- P/E Ratio
- PHH $47.27
- AVBP N/A
- Revenue Growth
- PHH N/A
- AVBP N/A
- 52 Week Low
- PHH $0.82
- AVBP $15.47
- 52 Week High
- PHH $41.49
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- PHH N/A
- AVBP 44.46
- Support Level
- PHH N/A
- AVBP $20.81
- Resistance Level
- PHH N/A
- AVBP $22.29
- Average True Range (ATR)
- PHH 0.00
- AVBP 0.98
- MACD
- PHH 0.00
- AVBP -0.03
- Stochastic Oscillator
- PHH 0.00
- AVBP 33.32
About PHH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.